Persistently low intact parathyroid hormone levels predict a progression of aortic arch calcification in incident hemodialysis patients

Clinical and Experimental Nephrology

Volumn 16, Issue 3, 2012, Pages 433-441

  Rhee, Harin ^a   Song, Sang Heon ^a,b   Kwak, Ihm Soo ^a   Lee, Soo Bong ^a   Lee, Dong Won ^a   Seong, Eun Young ^a   Kim, Il Young ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Hemodialysis; Parathyroid hormone; Vascular calcification

Indexed keywords

ANTIHYPERTENSIVE AGENT; PARATHYROID HORMONE;

ADULT; ANTERIOR POSTERIOR AXIS; ARTERY CALCIFICATION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; HYPOPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; PREVALENCE; SCORING SYSTEM; THORAX RADIOGRAPHY;

ADULT; AGED; AORTA, THORACIC; AORTIC DISEASES; CALCINOSIS; DISEASE PROGRESSION; FEMALE; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROGNOSIS; RENAL DIALYSIS;

EID: 84863720351     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0577-z     Document Type: Article

References (33)

1. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B. Vascular calcifications: Pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol. 2006;17:267-73.
2. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transpl. 2003;18:1731-40.
3. El-Abbadi M, Giachelli CM. Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: Current concepts at the bench. Curr Opin Nephrol Hypertens. 2005;14:519-24.
4. Ohya M, Otani H, Kimura K, Saika Y, Fujii R, Yukawa S, et al. Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol. 2011. Epub ahead of print.
5. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913-21.
6. Tamei N, Ogawa T, Ishida H, Ando Y, Nitta K. Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis. J Atheroscler Thromb. 2011;18:217-23.
7. Martin KJ, Gonzalez EA. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin J Am Soc Nephrol. 2011;6:440-6.
8. Ogata H, Koiwa F, Kinugasa E, Akizawa T. CKD-MBD: Impact on management of kidney disease. Clin Exp Nephrol. 2007;11(4): 261-8.
9. Cozzolino M, Brandenburg V. Paricalcitol and outcome: A manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". Clin Nephrol. 2009;71:593-601.
10. Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis. 2011;38:1351-7.
11. Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis. 2002;39:1245-54.
12. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15:770-9.
13. Bieglmayer C, Prager G, Niederle B. Kinetic analyses of parathyroid hormone clearance as measured by three rapid immunoassays during parathyroidectomy. Clin Chem. 2002;48:1731-8.
14. The guideline committee of the Japanese Society for Dialysis-Therapy. Guidelines for the management of secondary hyperparathyroidism in chronic dialysis patients. J Jpn Soc Dial Ther. 2006;36:1435-55.
15. Ogawa T, Ishida H, Matsuda N, Fujiu A, Matsuda A, Ito K, et al. Simple evaluation of aortic arch calcification by chest radiography in hemodialysis patients. Hemodial Int. 2009;13:301-6.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-201.
17. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for 2006 updates. Am J Kidney Dis. 2006;48 Suppl 1:S1-322.
18. Iribarren C, Sidney S, Sternfeld B, Browner WS. Calcification of the aortic arch: risk f actors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA. 2000; 283:2810-5.
19. Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH, Luft FC. A modified quantitative subjective global assessment of nutrition for dialysis patients. Nephrol Dial Transpl. 1999;14:1732-8.
20. Feroze U, Molnar MZ, Dukkipati R, Kovesdy CP, Kalantar-Zadeh K. Insights into nutritional and inflammatory aspects of low parathyroid hormone in dialysis patients. J Ren Nutr. 2011; 21:100-4.
21. Lafage-Proust MH, Combe C, Barthe N, Aparicio M. Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-Term protein and phosphorus restriction. J Clin Endocrinol Metab. 1999;84:512-9.
22. Galassi A, Spiegel DM, Bellasi A, Block GA, Raggi P. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transpl. 2006;21:3215-22.
23. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994;46: 855-61.
24. Cannata-Andia JB. Adynamic bone and chronic renal failure: An overview. Am J Med Sci. 2000;320:81-4.
25. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factoralpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation. 2000;102:2636-42.
26. Lencel P, Delplace S, Pilet P, Leterme D, Miellot F, Sourice S, et al. Cell-specific effects of TNF-Alpha and IL-1beta on alkaline phosphatase. Implication for syndesmophyte formation and vascular calcification. Lab Invest. 2011;91(10):1434-42.
27. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899-911.
28. Wang AY, Woo J, Wang M, Sea MM, Ip R, Li PK, et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol. 2001;12:1927-36.
29. Ikee R, Honda K, Oka M, Maesato K, Mano T, Moriya H, et al. Association of heart valve calcification with malnutrition-inflammation complex syndrome, beta-microglobulin, and carotid intima media thickness in patients on hemodialysis. Ther Apher Dial. 2008;12:464-8.
30. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15: 827-32.
31. Moe SM, O'Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P, et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transpl. 2003;18:1152-8.
32. Ogawa T, Ishida H, Akamatsu M, Matsuda N, Fujiu A, Ito K, et al. Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients. Int Urol Nephrol. 2010;42:187-94.
33. Noordzij M, Cranenburg EM, Engelsman LF, Hermans MM, Boeschoten EW, Brandenburg VM, et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transpl. 2011;26:1662-9.